In its interim report, Sanofi said that in 2025 it now expects sales to grow by a "high single-digit" percentage at constant exchange rates, instead of the "mid to high" previously forecast.

The healthcare group confirmed that it expects a strong rebound in operating EPS, with CGU growth "in the low double-digit percentage range" (excluding share buybacks), now including all charges from recently acquired businesses.

For Q2 2025, Sanofi reported operating EPS of €1.59, up 8.3% at CCE (+1.9% as reported), on sales of just under €10bn, up 10.1% at CCE (+6% as reported).

Sales of its nine new drugs and vaccines rose 47.3%. Eight years after its launch, Dupixent grew by more than 20%, driven by its launch in the treatment of COPD, management said.